Literature DB >> 14600372

Specific nonpeptide inhibitors of puromycin-sensitive aminopeptidase with a 2,4(1H,3H)-quinazolinedione skeleton.

Hiroki Kakuta1, Aya Tanatani, Kazuo Nagasawa, Yuichi Hashimoto.   

Abstract

Potent, specific, chemically stable and non-peptide/small-molecular inhibitors of puromycin-sensitive aminopeptidase, such as 3-(2,6-diethylphenyl)-2,4(1H,3H)-quinazolinedione (PAQ-22, 5), were prepared by the structural development of a potent PSA inhibitor, 2-(2,6-diethylphenyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dione (PIQ-22, 4). The design was carried out partly by applying electrostatic potential field information obtained from PIQ-22 (4) and its derivatives based on thalidomide (2). This information revealed that a positive electrostatic potential field around the benzylic methylene in the tetrahydroisoquinoline ring is necessary for potent activity. Lineweaver-Burk plot analysis showed that PAQ-22 (5) and its derivatives inhibit puromycin-sensitive aminopeptidase (PSA) in a non-competitive manner. These potent and specific PSA inhibitors showed dose-dependent cell invasion-inhibitory activity in a Matrigel assay using mouse melanoma B16F10/L5 cells, in spite of their low cell toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600372     DOI: 10.1248/cpb.51.1273

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  9 in total

1.  Rational design of substituted diarylureas: a scaffold for binding to G-quadruplex motifs.

Authors:  William C Drewe; Rupesh Nanjunda; Mekala Gunaratnam; Monica Beltran; Gary N Parkinson; Anthony P Reszka; W David Wilson; Stephen Neidle
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Authors:  Nathalie Vigneron; Violette Ferrari; Benoît J Van den Eynde; Peter Cresswell; Ralf M Leonhardt
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

3.  Synthesis of new quinazolin-2,4-diones as anti-Leishmania mexicana agents.

Authors:  Eduardo Enciso; Juan I Sarmiento-Sánchez; Héctor S López-Moreno; Adrián Ochoa-Terán; Ulises Osuna-Martínez; Evangelina Beltrán-López
Journal:  Mol Divers       Date:  2016-08-16       Impact factor: 2.943

4.  The catalytic and protein-protein interaction domains are required for APM1 function.

Authors:  Fazeeda N Hosein; Anindita Bandyopadhyay; Wendy Ann Peer; Angus S Murphy
Journal:  Plant Physiol       Date:  2010-02-12       Impact factor: 8.340

5.  I2/TBHP mediated domino synthesis of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-aryl/alkyl benzamides and evaluation of their anticancer and docking studies.

Authors:  Anil Kumar Soda; Phani Krishna C S; Sai Krishna Chilaka; Vamshi Krishna E; Sunil Misra; Sridhar Madabhushi
Journal:  RSC Adv       Date:  2022-06-06       Impact factor: 4.036

6.  Discovery of Quinazoline-2,4(1H,3H)-Dione Derivatives as Potential Antibacterial Agent: Design, Synthesis, and Their Antibacterial Activity.

Authors:  Nader M Boshta; Farag A El-Essawy; Mohammed B Alshammari; Safaa G Noreldein; Osama M Darwesh
Journal:  Molecules       Date:  2022-06-15       Impact factor: 4.927

Review 7.  The role of multifunctional M1 metallopeptidases in cell cycle progression.

Authors:  Wendy Ann Peer
Journal:  Ann Bot       Date:  2011-01-21       Impact factor: 4.357

8.  Aminobenzosuberone Scaffold as a Modular Chemical Tool for the Inhibition of Therapeutically Relevant M1 Aminopeptidases.

Authors:  Emmanuel Salomon; Marjorie Schmitt; Anil Kumar Marapaka; Athanasios Stamogiannos; Germain Revelant; Céline Schmitt; Sarah Alavi; Isabelle Florent; Anthony Addlagatta; Efstratios Stratikos; Céline Tarnus; Sébastien Albrecht
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

Review 9.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.